Last reviewed · How we verify
Elucirem (Gadopiclenol)
Gadopiclenol is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening T1 relaxation time of water protons in tissues.
Gadopiclenol is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening T1 relaxation time of water protons in tissues. Used for MRI contrast enhancement for diagnostic imaging of the central nervous system and body.
At a glance
| Generic name | Elucirem (Gadopiclenol) |
|---|---|
| Sponsor | Johns Hopkins University |
| Drug class | Gadolinium-based MRI contrast agent |
| Target | Water protons (T1 relaxation enhancement) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Gadopiclenol is a macrocyclic gadolinium chelate complex designed for use as an MRI contrast agent. It distributes in the extracellular space and increases signal intensity in T1-weighted MRI images by paramagnetic effects on nearby water molecules, improving visualization of tissue perfusion and anatomy. The macrocyclic structure provides enhanced stability and safety compared to linear gadolinium agents.
Approved indications
- MRI contrast enhancement for diagnostic imaging of the central nervous system and body
Common side effects
- Headache
- Nausea
- Dizziness
- Injection site reactions
Key clinical trials
- Screening for Brain Metastases (PHASE2)
- Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas (PHASE3)
- Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age (PHASE2)
- Gadopiclenol in Contrast Enhanced MRI of the Prostate (PHASE4)
- High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment (PHASE4)
- Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elucirem (Gadopiclenol) CI brief — competitive landscape report
- Elucirem (Gadopiclenol) updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI